Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vantia Therapeutics Ltd.

www.vantiatherapeutics.com

Latest From Vantia Therapeutics Ltd.

Pipeline Watch: Topline Phase III Results For Caplacizumab, Relugolix, Iclaprim

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?

Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.

BioPharmaceutical Research and Development Strategies

Royalty Rights To AMD Drug Spur $175 Million Capital Raise For Ophthotech

Money will finance 1,900-patient, 200-site Phase III trial for wet AMD drug Fovista, expected to work in concert with anti-VEGF therapies such as Lucentis to restore eye function. The transaction is just the latest ophthalmology financing involving Novo AS, SV Life Sciences and executives once with Eyetech.

BioPharmaceutical United States

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2011

Biopharma financing dropped in Q3 2011 to $1.3 billion, down from $6.3 billion in Q2. There were 20 M&A deals that totaled $30.9 billion, attributed mainly to the $27.7 million merger of PBMs Express Scripts and Medco. Almost a quarter of the alliances penned were for preclinical assets.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Respiratory, Pulmonary
  • Alias(es)
  • Vantia Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Vantia Therapeutics Ltd.
  • Senior Management
  • Andrew Crockett, CEO
    Stephen Donnelly, CFO
    Robert Haigh, PhD, CSO
  • Contact Info
  • Vantia Therapeutics Ltd.
    Phone: (44) 02380763400
    Southampton Science Pk.
    1 Venture Rd.
    Chilworth, Southampton, SO16 7NP
    UK
UsernamePublicRestriction

Register